ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia

British Journal of Haematology

Volumn 158, Issue 2, 2012, Pages 208-215

  Damm, Frederik ^a   Wagner, Katharina ^a   Görlich, Kerstin ^a   Morgan, Michael ^a   Thol, Felicitas ^a   Yun, Haiyang ^a   Delwel, Ruud ^b   Valk, Peter J M ^b   Löwenberg, Bob ^b   Heuser, Michael ^a   Ganser, Arnold ^a   Krauter, Jürgen ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukaemia; Gene mutations; ID1; Karyotype; Prognostic factors

Indexed keywords

FLT3 LIGAND; INHIBITOR OF DIFFERENTIATION 1; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; ID1 GENE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CCAAT-ENHANCER-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PROGNOSIS; REMISSION INDUCTION; RISK FACTORS; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84863461113     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09144.x     Document Type: Article

References (27)

1. Baldus, C.D., Tanner, S.M., Ruppert, A.S., Whitman, S.P., Archer, K.J., Marcucci, G., Caligiuri, M.A., Carroll, A.J., Vardiman, J.W., Powell, B.L., Allen, S.L., Moore, J.O., Larson, R.A., Kolitz, J.E., de la, C.A. & Bloomfield, C.D. (2003) BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood, 102, 1613-1618.
2. Cammenga, J., Mulloy, J.C., Berguido, F.J., MacGrogan, D., Viale, A. & Nimer, S.D. (2003) Induction of C/EBPalpha activity alters gene expression and differentiation of human CD34 + cells. Blood, 101, 2206-2214.
3. Damm, F., Heuser, M., Morgan, M., Yun, H., Göhring, G., Schlegelberger, B., Döhner, K., Ottmann, O., Lübbert, M., Heit, W., Kanz, L., Schlimok, G., Raghavachar, A., Fiedler, W., Kirchner, H., Döhner, H., Heil, G., Ganser, A. & Krauter, J. (2010) A single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in cytogenetically normal acute myeloid leukemia patients. Journal of Clinical Oncology, 28, 578-585.
4. Damm, F., Heuser, M., Morgan, M., Wagner, K., Gorlich, K., Grosshennig, A., Hamwi, I., Thol, F., Surdziel, E., Fiedler, W., Lubbert, M., Kanz, L., Reuter, C., Heil, G., Delwel, R., Lowenberg, B., Valk, P.J., Krauter, J. & Ganser, A. (2011) Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood, 117, 4561-4568.
5. Dohner, K., Schlenk, R.F., Habdank, M., Scholl, C., Rucker, F.G., Corbacioglu, A., Bullinger, L., Frohling, S. & Dohner, H. (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood, 106, 3740-3746.
6. Frohling, S., Schlenk, R.F., Stolze, I., Bihlmayr, J., Benner, A., Kreitmeier, S., Tobis, K., Dohner, H. & Dohner, K. (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. Journal of Clinical Oncology, 22, 624-633.
7. Green, C.L., Evans, C.M., Zhao, L., Hills, R.K., Burnett, A.K., Linch, D.C. & Gale, R.E. (2011) The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood, 118, 409-412.
8. Heil, G., Krauter, J., Raghavachar, A., Bergmann, L., Hoelzer, D., Fiedler, W., Lübbert, M., Noens, L., Schlimok, G., Arnold, R., Kirchner, H. & Ganser, A. (2004) Risk-adapted induction and consolidation therapy in adults with de novo AML aged
9. Heuser, M., Beutel, G., Krauter, J., Dohner, K., von, N.N., Schlegelberger, B. & Ganser, A. (2006) High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood, 108, 3898-3905.
10. Marcucci, G., Maharry, K., Radmacher, M.D., Mrozek, K., Vukosavljevic, T., Paschka, P., Whitman, S.P., Langer, C., Baldus, C.D., Liu, C.G., Ruppert, A.S., Powell, B.L., Carroll, A.J., Caligiuri, M.A., Kolitz, J.E., Larson, R.A. & Bloomfield, C.D. (2008) Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 26, 5078-5087.
11. Marcucci, G., Maharry, K., Wu, Y.Z., Radmacher, M.D., Mrozek, K., Margeson, D., Holland, K.B., Whitman, S.P., Becker, H., Schwind, S., Metzeler, K.H., Powell, B.L., Carter, T.H., Kolitz, J.E., Wetzler, M., Carroll, A.J., Baer, M.R., Caligiuri, M.A., Larson, R.A. & Bloomfield, C.D. (2010) IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 28, 2348-2355.
12. Metzeler, K.H., Dufour, A., Benthaus, T., Hummel, M., Sauerland, M.C., Heinecke, A., Berdel, W.E., Buchner, T., Wormann, B., Mansmann, U., Braess, J., Spiekermann, K., Hiddemann, W., Buske, C. & Bohlander, S.K. (2009) ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. Journal of Clinical Oncology, 27, 5031-5038.
13. Mitelman, F. (1995) ISCN: An International System for Human Cytogenetic Nomenclature. S. Karger, Basel, Switzerland.
14. Paschka, P., Marcucci, G., Ruppert, A.S., Whitman, S.P., Mrozek, K., Maharry, K., Langer, C., Baldus, C.D., Zhao, W., Powell, B.L., Baer, M.R., Carroll, A.J., Caligiuri, M.A., Kolitz, J.E., Larson, R.A. & Bloomfield, C.D. (2008) Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. Journal of Clinical Oncology, 26, 4595-4602.
15. Paschka, P., Schlenk, R.F., Gaidzik, V.I., Habdank, M., Kronke, J., Bullinger, L., Spath, D., Kayser, S., Zucknick, M., Gotze, K., Horst, H.A., Germing, U., Dohner, H. & Dohner, K. (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. Journal of Clinical Oncology, 28, 3636-3643.
16. Schlenk, R.F., Dohner, K., Krauter, J., Frohling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Spath, D., Morgan, M., Benner, A., Schlegelberger, B., Heil, G., Ganser, A. & Dohner, H. (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. The New England Journal of Medicine, 358, 1909-1918.
17. Sikder, H.A., Devlin, M.K., Dunlap, S., Ryu, B. & Alani, R.M. (2003) Id proteins in cell growth and tumorigenesis. Cancer Cell, 3, 525-530.
18. Suh, H.C., Leeanansaksiri, W., Ji, M., Klarmann, K.D., Renn, K., Gooya, J., Smith, D., McNiece, I., Lugthart, S., Valk, P.J., Delwel, R. & Keller, J.R. (2008) Id1 immortalizes hematopoietic progenitors in vitro and promotes a myeloproliferative disease in vivo. Oncogene, 27, 5612-5623.
19. Tam, W.F., Gu, T.L., Chen, J., Lee, B.H., Bullinger, L., Frohling, S., Wang, A., Monti, S., Golub, T.R. & Gilliland, D.G. (2008) Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood, 112, 1981-1992.
20. Tang, R., Hirsch, P., Fava, F., Lapusan, S., Marzac, C., Teyssandier, I., Pardo, J., Marie, J.P. & Legrand, O. (2009) High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia. Blood, 114, 2993-3000.
21. Taskesen, E., Bullinger, L., Corbacioglu, A., Sanders, M.A., Erpelinck, C.A., Wouters, B.J., van der Poel-van de Luytgaarde, S.C., Damm, F., Krauter, J., Ganser, A., Schlenk, R.F., Lowenberg, B., Delwel, R., Dohner, H., Valk, P.J. & Dohner, K. (2011) Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood, 117, 2469-2475.
22. Thol, F., Damm, F., Wagner, K., Gohring, G., Schlegelberger, B., Hoelzer, D., Lubbert, M., Heit, W., Kanz, L., Schlimok, G., Raghavachar, A., Fiedler, W., Kirchner, H., Heil, G., Heuser, M., Krauter, J. & Ganser, A. (2010) Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood, 116, 614-616.
23. Valk, P.J., Verhaak, R.G., Beijen, M.A., Erpelinck, C.A., Barjesteh van Waalwijk van Doorn-Khosrovani, S., Boer, J.M., Beverloo, H.B., Moorhouse, M.J., van der Spek, P.J., Lowenberg, B. & Delwel, R. (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. The New England Journal of Medicine, 350, 1617-1628.
24. Verhaak, R.G., Wouters, B.J., Erpelinck, C.A., Abbas, S., Beverloo, H.B., Lugthart, S., Lowenberg, B., Delwel, R. & Valk, P.J. (2009) Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica, 94, 131-134.
25. Virappane, P., Gale, R., Hills, R., Kakkas, I., Summers, K., Stevens, J., Allen, C., Green, C., Quentmeier, H., Drexler, H., Burnett, A., Linch, D., Bonnet, D., Lister, T.A. & Fitzgibbon, J. (2008) Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. Journal of Clinical Oncology, 26, 5429-5435.
26. Wagner, K., Zhang, P., Rosenbauer, F., Drescher, B., Kobayashi, S., Radomska, H.S., Kutok, J.L., Gilliland, D.G., Krauter, J. & Tenen, D.G. (2006) Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. Proceedings of the National Academy of Sciences of the United States of America, 103, 6338-6343.
27. Wagner, K., Damm, F., Gohring, G., Gorlich, K., Heuser, M., Schafer, I., Ottmann, O., Lubbert, M., Heit, W., Kanz, L., Schlimok, G., Raghavachar, A.A., Fiedler, W., Kirchner, H.H., Brugger, W., Zucknick, M., Schlegelberger, B., Heil, G., Ganser, A. & Krauter, J. (2010) Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol, 28, 2356-2364.